EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene Editing in Neurological Disorders: Role of CRISPR-Cas9 in Targeted Therapies

Shaik Aminabee, Mittapalli Meghana Sri Naga Chaitanya, Mohammad Ayesha Begum, Sree Kavya Jonnalagadda, Mudunuri Syamala Devi, Polukonda Thanmai, Moka Bhagya Naga Deepika, Saladhi Veera Mounika Lakshmi

Biomedical & Pharmacology Journal · 02.06.2026 · 01_Special issue (19) · 844

DOI: 10.13005/bpj/3396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical & Pharmacology Journal, online erschienen am 01.06.2026. Verfasst von Shaik Aminabee und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis are complex neurological disorders driven by intricate genetic and molecular mechanisms. Current therapies are mainly symptomatic and fail to correct underlying genetic defects. The advent of CRISPR-Cas9 gene-editing technology offers unprecedented opportunities to address these disorders at the genomic level through precise DNA editing, gene regulation, and epigenetic modulation. Preclinical studies using neuronal models, brain organoids, and transgenic animals have demonstrated the feasibility of correcting gene defects with CRISPR. Advances such as improved delivery systems, high-fidelity Cas9 variants, and base editing further strengthen its clinical potential. However, key challenges remain, including safe delivery across the blood–brain barrier, minimizing off-target effects, and addressing ethical concerns. Overall, CRISPR-Cas9 holds promise for integration into precision medicine to revolutionize treatment of neurodegenerative and neurodevelopmental diseases.

Zitieren

APA

Aminabee, S., Chaitanya, M. M. S. N., Begum, M. A., Jonnalagadda, S. K., Devi, M. S., Thanmai, P., Deepika, M. B. N., & Lakshmi, S. V. M. (2026). Gene Editing in Neurological Disorders: Role of CRISPR-Cas9 in Targeted Therapies. Biomedical & Pharmacology Journal, 01_Special issue(19), 844. https://doi.org/10.13005/bpj/3396

Vancouver

Aminabee S, Chaitanya MMSN, Begum MA, Jonnalagadda SK, Devi MS, Thanmai P, et al. Gene Editing in Neurological Disorders: Role of CRISPR-Cas9 in Targeted Therapies. Biomedical & Pharmacology Journal. 2026;01_Special issue(19):844. doi:10.13005/bpj/3396

BibTeX
@article{Aminabee2026,
  author = {Aminabee, Shaik and Chaitanya, Mittapalli Meghana Sri Naga and Begum, Mohammad Ayesha and Jonnalagadda, Sree Kavya and Devi, Mudunuri Syamala and Thanmai, Polukonda and Deepika, Moka Bhagya Naga and Lakshmi, Saladhi Veera Mounika},
  title = {Gene Editing in Neurological Disorders: Role of CRISPR-Cas9 in Targeted Therapies},
  journal = {Biomedical & Pharmacology Journal},
  year = {2026},
  volume = {01_Special issue},
  number = {19},
  pages = {844},
  doi = {10.13005/bpj/3396}
}
Kostenlos starten →